Cargando…
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum sa...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439265/ https://www.ncbi.nlm.nih.gov/pubmed/36056181 http://dx.doi.org/10.1038/s42003-022-03849-0 |
| _version_ | 1784782016773881856 |
|---|---|
| author | Trombetta, Claudia Maria Piccini, Giulia Pierleoni, Giulio Leonardi, Margherita Dapporto, Francesca Marchi, Serena Andreano, Emanuele Paciello, Ida Benincasa, Linda Lovreglio, Piero Buonvino, Nicola Decaro, Nicola Stufano, Angela Lorusso, Eleonora Bombardieri, Emilio Ruello, Antonella Viviani, Simonetta Rappuoli, Rino Molesti, Eleonora Manenti, Alessandro Montomoli, Emanuele |
| author_facet | Trombetta, Claudia Maria Piccini, Giulia Pierleoni, Giulio Leonardi, Margherita Dapporto, Francesca Marchi, Serena Andreano, Emanuele Paciello, Ida Benincasa, Linda Lovreglio, Piero Buonvino, Nicola Decaro, Nicola Stufano, Angela Lorusso, Eleonora Bombardieri, Emilio Ruello, Antonella Viviani, Simonetta Rappuoli, Rino Molesti, Eleonora Manenti, Alessandro Montomoli, Emanuele |
| author_sort | Trombetta, Claudia Maria |
| collection | PubMed |
| description | The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1. |
| format | Online Article Text |
| id | pubmed-9439265 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94392652022-09-04 Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations Trombetta, Claudia Maria Piccini, Giulia Pierleoni, Giulio Leonardi, Margherita Dapporto, Francesca Marchi, Serena Andreano, Emanuele Paciello, Ida Benincasa, Linda Lovreglio, Piero Buonvino, Nicola Decaro, Nicola Stufano, Angela Lorusso, Eleonora Bombardieri, Emilio Ruello, Antonella Viviani, Simonetta Rappuoli, Rino Molesti, Eleonora Manenti, Alessandro Montomoli, Emanuele Commun Biol Article The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1. Nature Publishing Group UK 2022-09-02 /pmc/articles/PMC9439265/ /pubmed/36056181 http://dx.doi.org/10.1038/s42003-022-03849-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Trombetta, Claudia Maria Piccini, Giulia Pierleoni, Giulio Leonardi, Margherita Dapporto, Francesca Marchi, Serena Andreano, Emanuele Paciello, Ida Benincasa, Linda Lovreglio, Piero Buonvino, Nicola Decaro, Nicola Stufano, Angela Lorusso, Eleonora Bombardieri, Emilio Ruello, Antonella Viviani, Simonetta Rappuoli, Rino Molesti, Eleonora Manenti, Alessandro Montomoli, Emanuele Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title | Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title_full | Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title_fullStr | Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title_full_unstemmed | Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title_short | Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| title_sort | immune response to sars-cov-2 omicron variant in patients and vaccinees following homologous and heterologous vaccinations |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439265/ https://www.ncbi.nlm.nih.gov/pubmed/36056181 http://dx.doi.org/10.1038/s42003-022-03849-0 |
| work_keys_str_mv | AT trombettaclaudiamaria immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT piccinigiulia immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT pierleonigiulio immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT leonardimargherita immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT dapportofrancesca immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT marchiserena immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT andreanoemanuele immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT pacielloida immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT benincasalinda immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT lovregliopiero immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT buonvinonicola immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT decaronicola immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT stufanoangela immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT lorussoeleonora immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT bombardieriemilio immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT ruelloantonella immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT vivianisimonetta immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT rappuolirino immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT molestieleonora immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT manentialessandro immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations AT montomoliemanuele immuneresponsetosarscov2omicronvariantinpatientsandvaccineesfollowinghomologousandheterologousvaccinations |